Characterization of novel anthracycline prodrugs activated by human β-glucuronidase for use in antibody-directed enzyme prodrug therapy
- 9 August 1996
- journal article
- Published by Elsevier BV in Biochemical Pharmacology
- Vol. 52 (3), 455-463
- https://doi.org/10.1016/0006-2952(96)00248-1
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- β-Glucuronyl carbamate based pro-moieties designed for prodrugs in ADEPTTetrahedron Letters, 1995
- Targeting enzymes for cancer therapy: old enzymes in new rolesBritish Journal of Cancer, 1994
- A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancerBritish Journal of Cancer, 1992
- Analysis of a conjugate between anti-carcinoembryonic antigen monoclonal antibody and alkaline phosphatase for specific activation of the prodrug etoposide phosphateCancer Immunology, Immunotherapy, 1992
- Human immune response to monoclonal antibody-enzyme conjugates in ADEPT pilot clinical trialCell Biochemistry and Biophysics, 1992
- Simple and sensitive quantification of anthracyclines in mouse atrial tissue using high-performance liquid chromatography and fluorescence detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1991
- Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans.Journal of Clinical Oncology, 1988
- Protein binding of anthraquinone glycosides, with special reference to adriamycinCancer Chemotherapy and Pharmacology, 1982
- The direct linear plot. A new graphical procedure for estimating enzyme kinetic parametersBiochemical Journal, 1974